Increased serum uric acid level predicts poor prognosis in mildly severe chronic heart failure with reduced ejection fraction. An analysis from the MECKI score research group.

Cardiopulmonary exercise test Heart failure Hemoglobin Kidney function Uric acid, prognosis

Journal

European journal of internal medicine
ISSN: 1879-0828
Titre abrégé: Eur J Intern Med
Pays: Netherlands
ID NLM: 9003220

Informations de publication

Date de publication:
02 2020
Historique:
received: 08 07 2019
revised: 21 10 2019
accepted: 07 11 2019
pubmed: 4 12 2019
medline: 16 2 2021
entrez: 3 12 2019
Statut: ppublish

Résumé

Hyperuricemia prognostic impact on clinical outcomes in chronic heart failure (HF) patients has been investigated with inconclusive results. Aim of the study was to evaluate the prognostic impact of serum uric acid (SUA) on long-term clinical outcomes in HF. An analysis of MECKI (Metabolic Exercise Cardiac Kidney Index) database, with median follow-up of 3.4 years. Relation between SUA and all-cause/ cardiovascular (CV) deaths have been analysed in 4,577 patients (3,688 males, age 62.7 ± 12.9 years), with reduced ejection fraction HF (35 ± 11%), peakVO SUA is confirmed to be associated with increased mortality, but in less severe HF only. However SUA did not show additional prognostic power to the MECKI score.

Sections du résumé

BACKGROUND
Hyperuricemia prognostic impact on clinical outcomes in chronic heart failure (HF) patients has been investigated with inconclusive results.
OBJECTIVES
Aim of the study was to evaluate the prognostic impact of serum uric acid (SUA) on long-term clinical outcomes in HF.
METHODS
An analysis of MECKI (Metabolic Exercise Cardiac Kidney Index) database, with median follow-up of 3.4 years.
RESULTS
Relation between SUA and all-cause/ cardiovascular (CV) deaths have been analysed in 4,577 patients (3,688 males, age 62.7 ± 12.9 years), with reduced ejection fraction HF (35 ± 11%), peakVO
CONCLUSIONS
SUA is confirmed to be associated with increased mortality, but in less severe HF only. However SUA did not show additional prognostic power to the MECKI score.

Identifiants

pubmed: 31787490
pii: S0953-6205(19)30390-5
doi: 10.1016/j.ejim.2019.11.003
pii:
doi:

Substances chimiques

Uric Acid 268B43MJ25

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

47-52

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Nothing to declare.

Auteurs

Massimo Francesco Piepoli (MF)

UOC Cardiologia, G da Saliceto Hospital, Piacenza, Italy; Department of Cardiology, University of Foggia, Foggia, Italy.

Elisabetta Salvioni (E)

Centro Cardiologico Monzino, IRCCS, Milano, Italy.

Ugo Corrà (U)

Cardiology Department, Istituti Clinici Scientifici Maugeri, Veruno Institute, Veruno, Italy.

Francesco Doni (F)

Cardiology Department, Istituti Clinici Scientifici Maugeri, Veruno Institute, Veruno, Italy.

Alice Bonomi (A)

Centro Cardiologico Monzino, IRCCS, Milano, Italy.

Rocco La Gioia (R)

Division of Cardiology, "S. Maugeri" Foundation, IRCCS, Institute of Cassano Murge, Bari, Italy.

Giuseppe Limongelli (G)

Cardiologia SUN, Ospedale Monaldi (Azienda dei Colli), Seconda Università di Napoli, Napoli, Italy.

Stefania Paolillo (S)

Department of Advanced Biomedical Sciences, Federico II University of Naples, Italy.

Gianfranco Sinagra (G)

Cardiovascular Department, Ospedali Riuniti and University of Trieste, Trieste, Italy.

Angela B Scardovi (AB)

Cardiology Division, Santo Spirito Hospital, Roma, Italy.

Rosa Raimondo (R)

Fondazione Salvatore Maugeri, IRCCS, Istituto Scientifico di Tradate, Italy.

Michele Emdin (M)

Fondazione Gabriele Monasterio, CNR-Regione Toscana, Pisa, Italy; Life Science Institute, Scuola Superiore Sant'Anna, Pisa, Italy.

Federica Re (F)

Cardiology Division, Cardiac Arrhythmia Center and Cardiomyopathies Unit, San Camillo-Forlanini Hospital, Roma, Italy.

Mariantonietta Cicoira (M)

Section of Cardiology, Department of Medicine, University of Verona, Verona, Italy.

Michele Correale (M)

Department of Cardiology, University of Foggia, Foggia, Italy.

Roberto Badagliacca (R)

Dipartimento di Scienze Cardiovascolari, Respiratorie, Nefrologiche, Anestesiologiche e Geriatriche, "Sapienza", Rome University, Rome, Italy.

Francesco Clemenza (F)

Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation IRCCS - ISMETT, Palermo, Italy.

Carlo Lombardi (C)

Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Piergiuseppe Agostoni (P)

Centro Cardiologico Monzino, IRCCS, Milano, Italy; Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milano, Milano, Italy. Electronic address: piergiuseppe.agostoni@unimi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH